Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma.

ABSTRACT:

Background

Patients with primary refractory and relapsed neuroblastoma have a poor prognosis since safe and effective chemotherapies for these patients are currently limited. The development of new chemotherapy regimens for these patients is imperative to improve survival outcomes.

Methods

We retrospectively analyzed 40 patients with refractory (n = 36) or relapsed (n = 4) neuroblastoma who received irinotecan, etoposide, and carboplatin (IREC) as a second-line treatment. We evaluated their therapeutic response and the toxicity of IREC. We also assessed the impact of UGT1A1 gene polymorphisms, which are involved in irinotecan metabolism, on outcomes and toxicity.

Results

A total of 112 cycles of IREC were administered to 40 patients with a median of 2 cycles per patie

SUBMITTER: Imaya M 

PROVIDER: S-EPMC9089216 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature